Osteoporosis is a common complication of rheumatoid arthritis （RA）. Denosumab，a human antibody against receptor activator of nuclear factor-kappa B ligand，can suppress the differentiation and activation of osteoclast，increase bone mineral density （BMD）， and reduce the incidence of fracture. Denosumab can be used in the treatment of rheumatoid arthritis. In the patients with RA，it can efficiently increase bone mineral density，suppress the progression of bone erosion，but it does not affect synovitis and disease activity. The combination of denosumab and disease-modifying anti-rheumatic drugs，can inhibit bone erosion synergistically with good tolerance and no increases in infection rates. We should concern about rare side effects，such as osteonecrosis of the jaw and atypical femoral fracture. Calcium and vitamin D supplementation with denosumab treatment is beneficial to prevent hypocalcemia. We should pay attention to the risk of bone mineral density decline and vertebral fractures after drug discontinuation. Denosumab discontinuation might be considered under the guidance of doctors. Administration of a bisphosphonate after denosumab discontinuation is recommended.